No Data
JP Morgan 2025: Jazz Pharmaceuticals Focusing on Oncology Pipeline
Jazz Pharmaceuticals Plc (JAZZ): Analysts Recommend This 52-Week High Stocks Now
Express News | Jazz Pharmaceuticals PLC - Expects to Meet 2024 Revenue Guidance
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Zymeworks Says It Has Enough Cash to Operate Through H2 2027
Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) Delivered A Weaker ROE Than Its Industry